BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21514034)

  • 21. Lethal perinatal osteogenesis imperfecta due to a type I collagen alpha 2(I) Gly to Arg substitution detected by chemical cleavage of an mRNA:cDNA sequence mismatch.
    Bateman JF; Moeller I; Hannagan M; Chan D; Cole WG
    Hum Mutat; 1992; 1(1):55-62. PubMed ID: 1284475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteogenesis imperfecta: clinical, biochemical and molecular findings.
    Venturi G; Tedeschi E; Mottes M; Valli M; Camilot M; Viglio S; Antoniazzi F; Tatò L
    Clin Genet; 2006 Aug; 70(2):131-9. PubMed ID: 16879195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four new cases of lethal osteogenesis imperfecta due to glycine substitutions in COL1A1 and genes. Mutations in brief no. 152. Online.
    Mottes M; Gomez Lira M; Zolezzi F; Valli M; Lisi V; Freising P
    Hum Mutat; 1998; 12(1):71-2. PubMed ID: 10627137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV.
    Ward LM; Lalic L; Roughley PJ; Glorieux FH
    Hum Mutat; 2001 May; 17(5):434. PubMed ID: 11317364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular findings in Brazilian patients with osteogenesis imperfecta.
    Reis FC; Alexandrino F; Steiner CE; Norato DY; Cavalcanti DP; Sartorato EL
    J Appl Genet; 2005; 46(1):105-8. PubMed ID: 15741671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans.
    Gajko-Galicka A
    Acta Biochim Pol; 2002; 49(2):433-41. PubMed ID: 12362985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COL1A1 mutation analysis in Lithuanian patients with osteogenesis imperfecta.
    Benusiené E; Kucinskas V
    J Appl Genet; 2003; 44(1):95-102. PubMed ID: 12590186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
    Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
    Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a mutation in the COL1A2 gene of type I collagen. The mosaic parent exhibits phenotypic features of a mild form of the disease.
    Edwards MJ; Wenstrup RJ; Byers PH; Cohn DH
    Hum Mutat; 1992; 1(1):47-54. PubMed ID: 1301191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV.
    Pollitt R; McMahon R; Nunn J; Bamford R; Afifi A; Bishop N; Dalton A
    Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entropic control of the relative stability of triple-helical collagen peptide models.
    Suárez E; Díaz N; Suárez D
    J Phys Chem B; 2008 Nov; 112(47):15248-55. PubMed ID: 18973364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collagen model peptides: Sequence dependence of triple-helix stability.
    Persikov AV; Ramshaw JA; Brodsky B
    Biopolymers; 2000; 55(6):436-50. PubMed ID: 11304671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanical properties of physiological and pathological models of collagen peptides investigated via steered molecular dynamics simulations.
    Gautieri A; Vesentini S; Montevecchi FM; Redaelli A
    J Biomech; 2008 Oct; 41(14):3073-7. PubMed ID: 18805526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular heterogeneity in osteogenesis imperfecta type I.
    Willing MC; Pruchno CJ; Byers PH
    Am J Med Genet; 1993 Jan; 45(2):223-7. PubMed ID: 8456806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel Gly to Arg substitution at position 388 of the alpha1 chain of type I collagen in lethal form of osteogenesis imperfecta.
    Galicka A; Wolczynski S; Lesniewicz R; Chyczewski L; Gindzienski A
    Acta Biochim Pol; 2002; 49(2):443-50. PubMed ID: 12362986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteogenesis imperfecta: prospects for molecular therapeutics.
    Forlino A; Marini JC
    Mol Genet Metab; 2000; 71(1-2):225-32. PubMed ID: 11001814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteogenesis imperfecta and its molecular diagnosis by determination of mutations of type I collagen genes.
    Tedeschi E; Antoniazzi F; Venturi G; Zamboni G; Tatò L
    Pediatr Endocrinol Rev; 2006 Sep; 4(1):40-6. PubMed ID: 17021582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haplotype analysis of collagen type I genes in the general population and in osteogenesis imperfecta families.
    Mottes M; Sangalli A; Pignatti PF
    Am J Med Genet; 1993 Jan; 45(2):217-22. PubMed ID: 8096115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NMR conformational and dynamic consequences of a gly to ser substitution in an osteogenesis imperfecta collagen model peptide.
    Li Y; Brodsky B; Baum J
    J Biol Chem; 2009 Jul; 284(31):20660-7. PubMed ID: 19451653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single molecule effects of osteogenesis imperfecta mutations in tropocollagen protein domains.
    Gautieri A; Vesentini S; Redaelli A; Buehler MJ
    Protein Sci; 2009 Jan; 18(1):161-8. PubMed ID: 19177360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.